- Home
- PAGP vs TERN Comparison
PAGP vs TERN Comparison
Compare PAGP & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$35.22
Company Overview
Basic Information| Metric | PAGP | TERN |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.7B |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PAGP | TERN |
|---|---|---|
| Price | $21.20 | $35.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $20.17 | ★ $48.60 |
| AVG Volume (30 Days) | 2.1M | ★ 2.3M |
| Earning Date | 02-06-2026 | 03-19-2026 |
| Dividend Yield | ★ 7.88% | N/A |
| EPS Growth | ★ 11.94 | N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $46,917,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.39 | N/A |
| P/E Ratio | $22.41 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.61 | $1.87 |
| 52 Week High | $21.97 | $48.26 |
Technical Indicators
Market Signals| Indicator | PAGP | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 69.30 | 52.55 |
| Support Level | $20.08 | $34.99 |
| Resistance Level | $21.23 | $38.97 |
| Average True Range (ATR) | 0.40 | 1.97 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 86.58 | 61.76 |
Price Performance
Historical Comparison PAGP
TERN
About PAGP Plains GP Holdings L.P. Units representing Limited Partner Interests
Plains GP Holdings LP provides transportation, storage, processing, fractionation, and marketing services for crude oil, refined products, natural gas liquids, liquefied petroleum gas, and related products. The group manages its operations through two operating segments: Crude Oil and NGL.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.